CYP2D6 and breast carcinoma: Two very recent systematic analyses of data from more than 13,000 patients reported “no clinically important association between CYP2D6 genotype and breast cancer survival in tamoxifen-treated women” 51 and that the overall effects of different CYP2D6 phenotypes on breast cancer outcomes are not clear 52.